The offering provides crucial funding for Allogene's pivotal ALPHA3 trial but comes at a significant dilution cost. The $2.00 offering price below the current market price suggests urgency for capital. Traders should monitor the full ALPHA3 trial results expected in 2028, as the interim MRD data shows promise but remains early-stage. The dilution and capital raise indicate the company needs substantial funding to advance its lead candidate.
Price Chart
Executive Summary
Allogene Therapeutics is raising $175 million through an 87.5 million share public offering at $2.00 per share, with net proceeds of $163.9 million after expenses. The funds will support clinical trials, R&D, and general corporate purposes. The offering follows positive interim data from its pivotal ALPHA3 trial showing 41.6% higher MRD clearance in the cema-cel arm versus observation.
Key Facts
- Offering 87,500,000 shares at $2.00 per share, raising $175 million in gross proceeds
- Net proceeds estimated at $163.9 million after underwriting discounts and expenses
- Proceeds will be used for clinical trials, R&D, general corporate purposes
- Interim data from ALPHA3 trial shows 58.3% MRD-negative rate in cema-cel arm vs 16.7% in observation arm
- Stock priced at $2.00 per share, below the April 14, 2026 closing price of $2.28
- Significant dilution of $0.56 per share for new investors
Financial Impact
$163.9 million in net proceeds with $0.56 per share dilution for new investors
Risk Factors
- Significant dilution of $0.56 per share for new investors
- Dependence on successful trial outcomes for future value creation
- High cash burn rate requiring substantial capital to fund clinical development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-157128 |
| Document: 0001193125-26-157128-index-headers.html | 0001193125-26-157128 |
| Document: 0001193125-26-157128-index.html | 0001193125-26-157128 |
| Document: 0001193125-26-157128.txt | 0001193125-26-157128 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 144 | $1.25 $1.25 | · 0.00% | ▲ +0.52% | $1.22 (−2.80%) |
Sep 2, 2026 7w ago | 8-K | $1.98 $1.98 | · 0.00% | ▼ −1.05% | $1.22 (−38.64%) |
Aug 21, 2026 9w ago | 144 | $2.03 $2.17 | ▲ +6.90% | ▲ +6.58% | $1.22 (−40.15%) |
Aug 21, 2026 9w ago | EFFECT | $2.09 $2.03 | ▲ +2.87% | ▲ +2.58% | $1.22 (+41.87%) |
Aug 6, 2026 11w ago | Institutional Cluster | $1.97 $2.01 | ▲ +2.03% | ▲ +1.42% | $1.22 (−38.32%) |
Jun 22, 2026 18w ago | 8-K | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.22 (+41.30%) |
Jun 22, 2026 18w ago | 424B5 | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.22 (+41.30%) |
May 28, 2026 21w ago | DEFA14A | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.22 (−44.01%) |
May 28, 2026 21w ago | 8-K | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.22 (−44.01%) |
May 28, 2026 21w ago | Press Release | $2.17 $2.15 | ▼ −0.92% | ▼ −1.20% | $1.22 (−44.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers